STOCK TITAN

Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Esperion (ESPR) to participate in the 23rd Annual Needham Virtual Healthcare Conference on April 9, 2024. The company aims to improve outcomes for patients with cardiovascular diseases by developing innovative medicines. Esperion focuses on reducing LDL-cholesterol levels to help patients reach their health goals.
Positive
  • None.
Negative
  • None.

ANN ARBOR, Mich., March 26, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the 23rd Annual Needham Virtual Healthcare Conference. Sheldon Koenig, President and CEO, will participate in a fireside chat on Tuesday, April 9, 2024, at 12:45 PM ET. The Esperion management team will also host investor meetings that same day.

To register for the live webcast, follow this link.

A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.

Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.

Esperion Contact Information: 
Investors:  
Alexis Callahan
investorrelations@esperion.com
(406) 539-1762 
  
Media:  
Tiffany Aldrich  
corporateteam@esperion.com
(616) 443-8438


FAQ

When will Esperion participate in the 23rd Annual Needham Virtual Healthcare Conference?

Esperion will participate in the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024.

What is Esperion's goal in developing medicines?

Esperion aims to improve outcomes for patients with cardiovascular and cardiometabolic diseases by developing innovative medicines.

How does Esperion help patients with high cholesterol?

Esperion focuses on reducing LDL-cholesterol levels to help patients with high cholesterol reach their health goals.

Where can investors access the live webcast of Esperion's participation in the conference?

Investors can access the live webcast on the investor and media section of Esperion's website.

Esperion Therapeutics, Inc.

NASDAQ:ESPR

ESPR Rankings

ESPR Latest News

ESPR Stock Data

386.38M
183.65M
0.45%
39.06%
10.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ANN ARBOR

About ESPR

esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.